Welcome to GLIOTRAIN
Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics
A MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA) Innovative Training Network (ITN)
About GLIOTRAIN
An estimated 240,000 cases of brain and nervous system tumours are diagnosed every year, worldwide and Glioblastoma (GBM) is the most frequent and aggressive brain tumour. New treatment options and effective precision medicine therapies are urgently required. GLIOTRAIN is a multi-sectoral industry-academia collaboration, funded by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie ITN initiative, that will work to identify novel strategies to treat GBM as well as investigating resistance mechanisms in this devastating disease.
Congratulations to Luxembourg Institute of Health (LIH) researchers and GLIOTRAIN PIs, Prof Dr Simone Niclou (Director of the Department of Oncology and group leader of the NORLUX Neuro-Oncology Laboratory) and Dr Anna Golebiewska (group leader of the NORLUX Neuro-Oncology Laboratory), who received the highly prestigious Outstanding Scientific Achievement award at the Luxembourg National Research Fund (FNR) awards, 2021.
Congratulations to GLIOTRAIN ESR Yahaya Yabo who recently won the LuxDoc ‘People’s Choice’ prize.
A conference organised by the GLIOTRAIN H2020-MSCA-ITN research network
Date: 14 July 2021 Time: 14:30 – 17:45 CEST (13:30 – 16:45 Irish + UK time)
